Anthony Cheung
Fondateur chez ENGENE HOLDINGS INC.
Fortune : 904 254 $ au 31/05/2024
Postes actifs de Anthony Cheung
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ENGENE HOLDINGS INC. | Directeur Technique/Scientifique/R&D | 24/04/2023 | - |
| Fondateur | 24/04/2023 | - | |
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Directeur/Membre du Conseil | - | - |
| Directeur Technique/Scientifique/R&D | 16/07/2018 | - | |
| Fondateur | - | - | |
| Directeur Général | 25/10/2011 | 16/07/2018 | |
| President | 25/10/2011 | 16/07/2018 | |
| Secrétaire Général | 01/01/1999 | 25/05/2011 |
Historique de carrière de Anthony Cheung
Formation de Anthony Cheung
| University of British Columbia | Undergraduate Degree |
| Tulane University School of Medicine | Doctorate Degree |
Statistiques
Internationale
| Canada | 4 |
| Etats-Unis | 2 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 2 |
| Director/Board Member | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ENGENE HOLDINGS INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
- Bourse
- Insiders
- Anthony Cheung
- Expérience
